Ollo M A, el Sokkary H, Darwish E, Khamis Y, Souka A R
Department of Obstetrics and Gynaecology, University of Alexandria, Egypt.
Contraception. 1990 Jul;42(1):29-34. doi: 10.1016/0010-7824(90)90089-e.
Ovarian function was studied in ten normal fertile women before and during the first cycle on a low-dose micropill containing 30 mcg ethinyl estradiol and 150 mcg L-norgestrel. In a control cycle and the first treatment cycle, steroid metabolites estrone-3-glucuronide (E1-3G) and pregnanediol-3 alpha-glucuronide (Pd-3G) were measured in daily early morning urine (EMU) samples. Also, luteinizing hormone (LH) was estimated during the expected periovulatory period. During the first cycle of micropill intake, ovarian function was suppressed in all cases. This is evidenced by significantly lower E1-3G and Pd-3G and absent midcycle LH peak compared to control cycles. The pattern of steroid metabolites was almost flat with no peaks. It is concluded that there is no need to cover the first cycle of micropill intake with other contraceptive methods.
对10名正常育龄妇女在服用含30微克炔雌醇和150微克左炔诺孕酮的低剂量微型避孕药前及第一个周期期间的卵巢功能进行了研究。在对照周期和第一个治疗周期中,测定了每日清晨尿(EMU)样本中的类固醇代谢物雌酮-3-葡萄糖醛酸苷(E1-3G)和孕二醇-3α-葡萄糖醛酸苷(Pd-3G)。此外,在预期的排卵期估算促黄体生成素(LH)。在服用微型避孕药的第一个周期中,所有病例的卵巢功能均受到抑制。与对照周期相比,E1-3G和Pd-3G显著降低且周期中期LH峰值消失,这证明了这一点。类固醇代谢物的模式几乎呈平稳状态,没有峰值。得出的结论是,无需用其他避孕方法覆盖微型避孕药摄入的第一个周期。